Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a variant.

As a widely used alkylating agent, cyclophosphamide often leads to various toxicities. Severe hepatotoxicity has been rarely reported in breast cancer patients receiving chemotherapy containing cyclophosphamide. Differences in cyclophosphamide metabolism may contribute to variability in adverse events of patients. Here, we report on a case of a 68-year-old Chinese female with breast cancer who experienced severe and prolonged hepatotoxicity induced by cyclophosphamide. Pharmacogenetic tests showed that she was a carrier of allele and this is the first case of a variant in the Han Chinese population so far reported. In addition, the patient was also a carrier of an variant potentially contributing to the occurrence of hepatotoxicity. and genotyping may play a role in guiding cyclophosphamide therapy.